GRAIL (GRAL) Research Hub

GRAIL (GRAL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 139.91 USD (+5.55%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.81, market cap 3.08B. This hub links to the full technical, earnings and options research available for GRAL.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close139.91 USD (+5.55%)
52-week range57.51 USD – 166.48 USD
Trend regimeRange
14-day RSI51.8 (Neutral)
Trailing P/E-6.81
Market cap3.08B
Dividend yield0.00%
Next earnings2026-08-11

Available research for GRAL

Earnings

GRAL earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -6.81. Updated 2026-07-23.

Options: Covered Call

Covered Call on GRAL: how it works, illustrative setup around the real 139.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on GRAL: how it works, illustrative setup around the real 139.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on GRAL: how it works, illustrative setup around the real 139.91 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

GRAL technical analysis: range, last 139.91 USD, RSI 51.8, 52w range 57.51 USD–166.48 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is GRAL in?

GRAIL (GRAL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is GRAL in an uptrend or downtrend?

As of 2026-10-26, GRAL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is GRAL's trailing P/E ratio?

GRAL's trailing P/E is -6.81, with a market cap of 3.08B. See the earnings research page for full valuation detail.

When does GRAL next report earnings?

GRAL is next scheduled to report earnings on 2026-08-11.